NovoCure and Omeros present two distinct investment cases in the emerging pharmaceutical space. NovoCure, which markets Tumor Treating Fields devices for cancer, reported fiscal 2025 revenue of nearly $655.4 million, an 8.3% increase, but posted a net loss of roughly $136.2 million and negative free cash flow of $75.7 million. Omeros is transitioning to a commercial-stage company following the late 2025 FDA approval of Yartemlea for TA-TMA, and it reported first-quarter 2026 sales of $9.89 million along with net income of $56.06 million, boosted by upfront payments from a partnership with Novo Nordisk. NovoCure trades at a price-to-sales ratio of 2.4 times, while Omeros carries a much higher multiple of 74.3 times. Analysts project NovoCure will not generate free cash flow until fiscal 2028, whereas Omeros is expected to reach profitability by 2028, making it a potentially safer long-term bet despite its premium valuation.
Novocure LtdNovoCure reported a net loss and negative free cash flow, with analysts projecting no free cash flow until fiscal 2028.
Omeros CorporationOmeros reported net income of $56.06 million, boosted by upfront payments from a partnership with Novo Nordisk, and is expected to reach profitability by 2028.
Zai Lab Ltd
Novo Nordisk A/S